Journal article
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
EDMB Kroon, J Ananworanich, A Pagliuzza, A Rhodes, N Phanuphak, L Trautmann, JL Mitchell, M Chintanaphol, J Intasan, S Pinyakorn, K Benjapornpong, J Judy Chang, DJ Colby, N Chomchey, JLK Fletcher, K Eubanks, H Yang, J Kapson, A Dantanarayana, S Tennakoon Show all
Journal of Virus Eradication | Published : 2020
Abstract
Objective and Design: A randomized, open-label pilot study in individuals treated with antiretroviral therapy (ART) since acute HIV infection (AHI) with a regimen including a histone deacetylase inhibitor to induce HIV from latency and control HIV replication during subsequent treatment interruption (TI). Methods: Fifteen participants who initiated ART at AHI were randomized to vorinostat/hydroxychloroquine/ maraviroc (VHM) plus ART (n ¼ 10) or ART alone (n ¼ 5). The VHM arm received three 14-day vorinostat cycles within 10 weeks before TI. ART was resumed for plasma viral load (VL) > 1,000 HIV RNA copies/mL. Primary outcome was proportion of participants on VHM þ ART versus ART only with VL..
View full abstractGrants
Awarded by American Foundation for Aging Research
Funding Acknowledgements
We would like to thank the study participants who committed so much of their time for this study. The participants were from the RV254 acute HIV infection study, which is supported by cooperative agreements (W81XWH-07-2-0067, W81XWH-11-2-0174) between the Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., and the US Department of the Army and by an intramural grant from the Thai Red Cross AIDS Research Centre. The US Army Medical Research Acquisition Activity (820 Chandler Street, Fort Detrick, MD 21702-5014, USA) is the awarding and administering acquisition office for the cooperative agreement. Antiretroviral therapy for RV254 participants was supported by the Thai Government Pharmaceutical Organization, Gilead, Merck and ViiV Healthcare. This work was also funded in part by 1R01NS084911-01 from the National Institute of Neurologic Disorders and Stroke and with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E and by 1R01AI108433 from the National Institute of Allergy and Infectious Diseases. SRL, JJC, AR, AD and ST are supported by National Health and Medical Research Council of Australia (NHMRC Program Grant GNT1052979) and the National Institutes for Health Delaney AIDS Research Enterprise (DARE AI096109 and AI126611), and the American Foundation for AIDS Research. SRL is an NHMRC practitioner fellow.We thank Brandie A. Fullmer for work on the single-copy HIV RNA assay. We thank the staff from SEARCH and the HIV-NAT laboratory at the Thai Red Cross AIDS Research Centre for their valuable contributions to this study. We also thank Cooper Human Systems, Nashua, NH, USA for providing funding for vorinostat.